Book a Meeting

BetterBet™ Anti-CD19, a FcγRIIB Binding Enhanced Antibody (CAT#: AES-0622-ZP376) Datasheet

Target
CD19
Description
Although Recycling Antibody/Sweeping antibody can increase antigen clearance by about 50-fold in mice, it is less effective in primates. In order to enable the function of recycling antibody in humans, we developed FcγRIIB selective binding technology. FcγRIIB Binding Enhanced Antibody achieved by modifying the Fc of the antibody to increase the affinity of the antibody with FcγRIIb. FcγRIIb plays a major role in the clearance of antibody-antigen complexes by hepatic sinusoidal endothelial cells, therefore increasing the affinity of FcγRIIb for antibodies can accelerate the clearance of antibody-antigen complexes. These antibodies not only bind to target antigens in plasma, but also eliminate or remove them. They are expected to enhance cellular uptake of antibody-antigen complexes in primates/humans.
Applications
Enhancing primate/human antigen eliminating
Technology
FcγRIIB selective binding technology

Cooperation Seeking

CD19
Official Name
CD19 molecule
Background
CD19; CD19 molecule; B4; CVID3; B-lymphocyte antigen CD19; differentiation antigen CD19; T-cell surface antigen Leu-12; B-lymphocyte surface antigen B4

Due to high homology between inhibitory FcγRIIB and activating FcγRIIA, no successful Fc engineering to selectively enhance FcγRIIB binding has been reported. Since FcγRIIA is expressed on platelet, antibody could crosslink platelets by binding to FcγRIIA expressed on platelet, and has a risk of inducing thrombosis. Therefore, generation of novel Fc variant (FcγRIIB Binding Enhanced Antibody) with selective enhancement of FcγRIIB binding is neccessary. Engineered FcγRIIB Binding Enhanced Antibody could increase efficacy by inducing inhibitory signal into immune cell with strong FcγRIIB binding, in addition to neutralization of immune-activating antigen.

Related Products

Non-fucosylated Anti-Human CD19 Therapeutic Antibody, an ADCC-Enhanced Biobetter [Lot: CB20-PZ101] (CAT#: BioBet-101ZP)
ADCC-Enhanced Anti-Human CD19 (Loncastuximab) Antibody, a biobetter (CAT#: BioBet-CB-030LX)
Highly Galactosylated Anti-CD19 SGN-CD19A(Denintuzumab mafodotin), a Biobetter Antibody (CAT#: BioBet-GA-105ZP)
Non-Fucosylated Anti-Human CD19 (4G7) Therapeutic Antibody, an ADCC-Enhanced Biobetter (CAT#: BioBet-1693ZP)
ADCC-Enhanced Anti-Human CD19 (Loncastuximab) Antibody, a biobetter (CAT#: BioBet-CB-010LX)
Non-fucosylated Anti-Human CD19 Therapeutic Antibody, an ADCC-Enhanced Biobetter [Lot: CB20-PZ10] (CAT#: BioBet-010ZP)
Non-Fucosylated Anti-Human CD19 (GBR 401) Therapeutic Antibody, an ADCC-Enhanced Biobetter (CAT#: BioBet-1794ZP)
Non-Fucosylated Anti-Human CD19 (R005-1) Therapeutic Antibody, an ADCC-Enhanced Biobetter (CAT#: BioBet-1694ZP)

All products and services are for Research Use Only. Do Not use in humans.

ONLINE INQUIRY

Creative Biolabs has established a team of customer support scientists ready to discuss ADCC/CDC optimization strategies, antibody production, bioinformatics analysis and other molecular biology/biotechnology issues.

  • *
  • *
  • *
USA

UK

Germany